Tubulis Technologies generates uniquely matched protein-drug conjugates.
Tubulis Technologies has raised €379M across 3 funding rounds from 18 investors, most recently a Series C round in Oct 2025. Based in Munich, Germany; founded 2019; active in Healthtech. Data as of 6 Aug 2026.
Timing: in window vs cohort gap · momentum up. Funding-only estimates, not predictions and not investment advice — see signals.
| Date | Stage | Amount | Investors |
|---|
| 2025-10-15 | Series C | €308M | Andera Partners,Ascenta Capital,Bayern Kapital,Deep Track Capital,EQT Life Sciences,Existing investors+8 more | View deal → |
| 2022-05-03 | Series B | €60M | Andera Partners,Bayern Kapital,BioMedPartners,Coparion,Evotec,FundPlus+3 more | View deal → |
| 2020-07-21 | Series A | €11M | BioMedPartners,High-Tech Grunderfonds | View deal → |
